GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: compound 11d [Zetterberg et al., 2022] | Example 44 [WO2016120403A1] | GB-1211
Compound class:
Synthetic organic
Comment: GB1211 is an orally active small molecule galectin-3 inhibitor [1,5]. It was developed by Galecto Biotech for the treatment of fibrotic disease and cancer. In the fibrotic setting, blocking galectin-3's biological function is predicted to combat the enhanced TGF-β receptor-mediated macrophage differentiation and myofibroblast activation that drives pathological fibrotic changes [2-4].
|
|
|||||||||||||||||||||||||||||||||||
Classification ![]() |
|
| Compound class | Synthetic organic |
IUPAC Name ![]() |
| 2-(5-bromopyridin-3-yl)sulfanyl-6-(hydroxymethyl)-4-[4-(3,4,5-trifluorophenyl)triazol-1-yl]oxane-3,5-diol |
Synonyms ![]() |
| compound 11d [Zetterberg et al., 2022] | Example 44 [WO2016120403A1] | GB-1211 |
Database Links ![]() |
|
| GtoPdb PubChem SID | 434122262 |
| PubChem CID | 132201704 |
| Search Google for chemical match using the InChIKey | FNCLKJPMEFPXOR-UHFFFAOYSA-N |
| Search Google for chemicals with the same backbone | FNCLKJPMEFPXOR |
| UniChem Compound Search for chemical match using the InChIKey | FNCLKJPMEFPXOR-UHFFFAOYSA-N |
| UniChem Connectivity Search for chemical match using the InChIKey | FNCLKJPMEFPXOR-UHFFFAOYSA-N |